Skip to main content

Rykindo FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 17, 2023.

FDA Approved: Yes (First approved January 13, 2023)
Brand name: Rykindo
Generic name: risperidone
Dosage form: for Extended-Release Injectable Suspension
Company: Luye Pharma Group
Treatment for: Schizophrenia, Bipolar Disorder

Rykindo (risperidone) is a long-acting injection formulation of the approved atypical antipsychotic risperidone for the treatment of schizophrenia and bipolar I disorder in adults.

Development timeline for Rykindo

Jan 15, 2023Approval FDA Approves Rykindo (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Bipolar 1 Disorder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.